A new model for ductal carcinoma in situ suggests strategies for treatment

Breast Cancer Research

Volumn 4, Issue 5, 2002, Pages 176-178

  Gullick, William John ^a  

^a UNIVERSITY OF KENT   (United Kingdom)

Author keywords

Ductal carcinoma in situ; Growth factor receptor; Tyrosine kinase inhibitor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; ONCOPROTEIN; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; BREAST DUCT; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER SCREENING; CARCINOMA IN SITU; CELL CULTURE; CONTROLLED STUDY; DRUG SELECTIVITY; GENE ACTIVATION; GENE OVEREXPRESSION; GENE TARGETING; GROWTH INHIBITION; HUMAN; MAMMOGRAPHY; MOUSE; NONHUMAN; PHENOTYPE; RECEPTOR UPREGULATION; TUMOR XENOGRAFT;

ANIMAL; ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HUMAN; HUMANS; MAMMOGRAPHY; MODELS, BIOLOGICAL; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 0035995596     PISSN: 14655411     EISSN: None     Source Type: Journal    
DOI: 10.1186/bcr447     Document Type: Article

References (15)

1. Histological and biological evolution of human premalignant breast disease
2. A working model for the time sequence of genetic changes in breast tumorigenesis
3. Overexpression of the c-erbB-2 oncoprotein: Why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance?
4. The p53 tumor suppressor gene in ductal carcinoma in situ of the breast
5. HER2 as a prognostic and predictive marker for breast cancer
6. Relationship between c-erbB-2 immunoreactivity and thymidine labelling index in breast carcinoma in situ
7. ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini
8. Functional culture models to study mechanisms governing apoptosis in normal and malignant mammary epithelial cells
9. Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers
10. Untangling the ErbB signalling network
11. The Type 1 growth factor receptors and their ligands considered as a complex system
12. The current treatment of ductal carcinoma in situ
13. The management of ductal carcinoma in situ of the breast
14. Clinical practice guidelines for the care and treatment of breast cancer: The management of ductal carcinoma in situ
15. Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation